Enliven Therapeutics, Inc. (ELVN) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
ELVN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ELVN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export ELVN earnings history in CSV or JSON format
Free sign-in required to download data
Enliven Therapeutics, Inc. (ELVN) Earnings Overview
As of May 8, 2026, Enliven Therapeutics, Inc. (ELVN) reported trailing twelve-month net income of -$104M, reflecting +3.2% year-over-year growth. The company earned $-1.83 per diluted share over the past four quarters.
Looking at the long-term picture, ELVN's historical earnings data spans multiple years. The company achieved its highest annual net income of $0 in fiscal 2017.
Enliven Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), RVMD (-$1.37B net income), IMVT (-$464M net income), ELVN has comparable earnings metrics. Compare ELVN vs KYMR →
ELVN Earnings vs Peers
Earnings metrics vs comparable public companies
ELVN Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$104M | -16.5% | -$120M | $-1.83 | - | - |
| 2024 | -$89M | -24.4% | -$105M | $-1.89 | - | - |
| 2023 | -$72M | -90.1% | -$84M | $-2.01 | - | - |
| 2022 | -$38M | -52.2% | -$39M | $-6.03 | - | - |
| 2021 | -$25M | -30.4% | -$25M | $-3.17 | - | - |
| 2020 | -$19M | +19.2% | -$9M | $-4.31 | - | - |
| 2019 | -$23M | -107.0% | -$24M | $-5.43 | - | - |
| 2018 | -$11M | - | -$11M | $-2.62 | - | - |
| 2017 | $0 | - | -$9M | $0.00 | - | - |
See ELVN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ELVN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ELVN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonELVN — Frequently Asked Questions
Quick answers to the most common questions about buying ELVN stock.
Is ELVN growing earnings?
ELVN EPS of $-1.83 reflects slowing growth at +3.2%, below the 5-year CAGR of N/A. TTM net income is $-104M. Expansion rate has moderated.
What are ELVN's profit margins?
Enliven Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ELVN's earnings?
ELVN earnings data spans 2017-2025. The current earnings trend is +3.2% YoY. Historical data enables comparison across business cycles.